益方生物科技（上海）有限公司是一家成立于2013年的创业型生物医药公司，致力于肿瘤，肿瘤免疫，代谢领域的新药研发，公司产品管线已包含肺癌、乳腺癌，肿瘤免疫和痛风等领域靶向治疗的小分子候选药物，同时公司也在积极开发其他肿瘤及免疫肿瘤靶点的药物。公司目前有四个自主研发的1类新药，分别在中、美两地进行临床一、二期试验。 益方的目标不仅是要让中国而且是要让全世界的患者从我们研发的新药中受益，与此同时，我们也在资本市场上获得认可（2017年获得奥博资本与礼来亚洲基金的投资），与他们的战略合作将为公司今后的方向打下坚实的基础，在未来的全球医药市场上获得快速发展。
View Top Employees from 益方生物 InventisBio| Website | http://www.inventisbio.com/ |
| Revenue | $13.3 million |
| Funding | $247 million |
| Employees | 28 (21 on RocketReach) |
| Founded | 2013 |
| Phone | (973) 301-8000 |
| Fax | (973) 301-8002 |
| Industry | Pharmaceutical Manufacturing, Drug Stores & Pharmacies, Biopharma, Retail, Biotechnology, Health Care, Science and Engineering, Pharmaceutical |
| Competitors | Frost Biologic, Immunohelix, Orphagen Pharmaceuticals, Pharma Models LLC, Suntec Corporation |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular 益方生物 InventisBio employee's phone or email?
益方生物 InventisBio Questions
The 益方生物 InventisBio annual revenue was $13.3 million in 2024.
Jie XU is the Director of Business Development of 益方生物 InventisBio.
21 people are employed at 益方生物 InventisBio.
The NAICS codes for 益方生物 InventisBio are [325, 32, 32541, 3254].
The SIC codes for 益方生物 InventisBio are [283, 28].
Top 益方生物 InventisBio Employees
-
2
-
View
Dongmei Qiang
Vice President, Pharmaceutical and Analytical Development at 益方生物 InventisBio
San Francisco, CA, US32 -
2
-
25+
-
ViewYounong Yu
Senior Director, Discovery Chemistry at Inventisbio at 益方生物 InventisBio
East Brunswick, NJ, US13 -
1
-
31
-
1
-
1
-
1
Related Companies
